Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Marinus Pharmaceuticals excels in Q4 with ZTALMY sales surge

Marinus Pharmaceuticals' Q4 2022 performance reflects strong demand for ZTALMY and progress in clinical pipeline development.
The company's strengths lie in successful product launches, intellectual property advancements, and a positive outlook for 2023.
Challenges include careful decision-making processes and efforts to expand patient reach and market awareness.
Opportunities for Marinus include global market expansion, increased disease diagnosis rates, and innovative drug development strategies.

Marinus Pharmaceuticals reports steady growth and strategic expansion opportunities

Marinus Pharmaceuticals demonstrated steady revenue growth and operational progress in advancing clinical programs and expanding market reach.
The company faces challenges in product development, trial management, and market dynamics but is well-positioned to capitalize on growth opportunities.
Strategic initiatives in IP portfolio expansion, market expansion in new regions, and a focus on innovation and patient safety underpin the company's growth trajectory.
CEO's strategic vision, emphasis on market exclusivity, and confidence in franchise longevity signal a strong foundation for future success and market leadership.

Marinus Pharmaceuticals reports robust earnings, faces trial enrollment challenges

Marinus Pharmaceuticals shows strong financial performance and operational resilience in Q2 2023.
The company faces challenges in trial enrollment delays but maintains a focus on innovation and market expansion.
Opportunities lie in product diversification, market growth, and demonstrating the value of their drug portfolio.

Marinus Pharmaceuticals surpasses revenue targets, eyes global expansion opportunities

Marinus Pharmaceuticals demonstrated strong financial performance in Q3 2023, with revenue exceeding expectations and a healthy cash position.
The company's strategic focus on expanding ZTALMY access globally and prioritizing high-value patient populations showcases a promising growth trajectory.
Challenges such as high screening attrition rates and gross to net deductions are being addressed, while opportunities in patient population expansion and program pricing present avenues for future success.
Overall, Marinus Pharmaceuticals is well-positioned for continued growth and innovation in the pharmaceutical market, supported by ongoing clinical trials and strategic initiatives.

Marinus Pharmaceuticals beats revenue targets, eyes blockbuster franchise growth

Marinus Pharmaceuticals showed strong performance in Q4 2023 with revenue exceeding guidance
Financially, the company is well-positioned with a healthy cash balance and controlled operating expenses
Challenges include increased R&D expenses and cash burn, but opportunities lie in revenue growth and market readiness
Excitement surrounds the progress of IV ganaxolone trials and potential blockbuster franchise plans

Marinus Pharmaceuticals excels with ZTALMY profitability and global expansion

Marinus Pharmaceuticals has shown strong performance with ZTALMY and the TSC trial, supported by strategic financial actions and operational advancements.
While facing challenges in maintaining growth momentum and patient acquisition, the company is well-positioned for global expansion and profitability post-TSC launch.
Opportunities lie in expanding market access, enhancing manufacturing capabilities, and preparing for a successful launch in key regions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals announces the pricing of an underwritten public offering of 5 million shares of its common stock for gross proceeds of $70MM.

Marinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common Stock

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals announces an underwritten public offering of its common stock.

Marinus Pharmaceuticals Announces Underwritten Public Offering of Common Stock

RADNOR, Pa.--(BUSINESS WIRE)-- #AES2020--Marinus Pharmaceuticals will provide additional ganaxolone data during #AES2020 Scientific Exhibit.

Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update

RADNOR, Pa.--(BUSINESS WIRE)-- #AES2020--Marinus Pharmaceuticals will host a webinar with updates on its programs in status epilepticus, CDD, and TSC at #AES2020.

Marinus Pharmaceuticals to Host Virtual Investor Event at AES On December 7, 2020

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #AES2020--Marinus Pharma. to present updates and data from its trials in CDKL5 and refractory status epileptics at American Epilepsy Society's conference.

Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual Meeting

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q3 2020 Results - Earnings Call Transcript

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #CDKL5--Marinus Pharmaceuticals provides a business update following its "milestone" third quarter.

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #ChiefCommercialOfficer--Marinus Pharmaceuticals appoints Christy Shafer as Chief Commercial Officer. Shafer will report to CEO Dr. Scott Braunstein, and comes from Alexion.

Marinus Pharmaceuticals Appoints Christy Shafer as Chief Commercial Officer

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #FY2020--Marinus Pharmaceuticals will announce its financial results for the third quarter on November 9, 2020 following the close of market.

Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2020 Financial Results on November 9, 2020

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #GuggenheimHealthcareTakes--Marinus Pharmaceuticals announced that company management will participate in a number of investor healthcare conferences from late Oct. through Nov.

Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare Conferences

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #BARDA--Marinus Pharmaceuticals has satisfied the FDA's protocol-specific questions for its Phase 3 trial in RSE and announces VPs, Clinical Development.

Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS--Marinus Pharmaceuticals announced that it will effect a one-for-four reverse stock split of its common stock at 5:00 pm ET today.

Marinus Announces One-for-Four Reverse Stock Split

Virtus LifeSci Biotech Clinical Trials ETF

Principal Healthcare Innovators Index ETF

Defiance Nasdaq Junior Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Novus Therapeutics

Invesco DWA Healthcare Momentum ETF

Cassava Sciences Inc

Wave Life Sciences

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Healthcare ETFs, Stocks That Gained Double Digits Last Week

Immunomedics

Vaxart

Find out what's behind their big run-ups to see if they can make it happen again.

3 Biotech Stocks That Surged Last Week

The announcement of positive topline results in a late-stage epilepsy trial prompted a rally in Marinus Pharmaceuticals Inc.

Why This Epilepsy Study Is Huge for Marinus Pharmaceuticals

Investors are thrilled with the results from a late-stage clinical study of the company's only pipeline drug candidate.

Why Marinus Pharmaceuticals Stock Skyrocketed 80% Higher Today

Shares of small-cap biopharma Marinus Pharmaceuticals Inc (NASDAQ: MRNS) were moving sharply higher to a new 52-week high Tuesday following the release of positive results for ganaxolone, the only investigational asset in its pipeline.

Why Marinus Pharma Shares Are Rocketing Higher

Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Marinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in Session

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #CDKL5--Marinus Pharmaceuticals' management will present at three investor conferences the week of September 14.

Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences

Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #BizUpdate--Marinus Pharmaceuticals provides an update on its clinical development activities and reports financial results for the second quarter of 2020.

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

Marinus Pharmaceuticals (NASDAQ: MRNS) shares are trading higher on Thursday after the company announced it has received FDA rare pediatric disease designation for Ganaxolone for the treatment of CDKL5 deficiency disorder.

Why Marinus Pharmaceuticals Is Trading Higher Today

RADNOR, Pa.--(BUSINESS WIRE)-- #CDKL5--Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)

RADNOR, Pa.--(BUSINESS WIRE)-- #ClinicalTrial--Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Appoints Charles Austin to Board of Directors

RADNOR, Pa., June  30, 2020  (GLOBE NEWSWIRE) --  Marinus Pharmaceuticals, Inc.  (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided a pipeline update in advance of it clinical and commercial overview webinar to be held today,  Tuesday, June 30, 2020 from 8am – 10:30am Eastern Time.

News for Marinus Pharmaceuticals Stock (MRNS)